Abstract
Autologous brain tumor specific CTLs were induced from the patient's PBL by a mixed lymphocyte-tumor culture, and were maintained for more than 2 months in a medium containing exogenous ILr2. The autologous T cell line containing specific CTL was administered into the tumor-bed for the treatment of malignant glioma. In 2 cases out of 5, tumors regressed more than 50% in diameter. One of these patients is still alive now with full of his social activities, and it is 104 weeks after the initiation of the immunotherapy. Autologous T cell lines were safely administered in all cases without any complications nor toxicities.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Millis GB, Carlson G, Paetkau V: Generation of cytotoxic lymphocytes to syngeneic tumors by using co-stimulator (interleukin 2); in vivo activity. J Immunol 125:1904–1909, 1980.
Cheever MA, Greenberg PD, Fefer A: Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and non-specifically expanded by culture with interleukin 2. J Immunol 126:1318–1322, 1981.
Cheever MA, Greenberg PD, Fefer A, Gillis S: Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2. J Exp Med 155:968–980, 1982.
Eberlein TJ, Rosenstein M, Spiess P, Wesley R, Rosenberg SA: Adoptive chemoimmunotherapy of a syngeneic murine lymphoma with long-term lymphoid cell lines expanded in T cell growth factor. Cancer Immunol Immunother 13:5–13, 1982.
Eberlein TJ, Rosenstein M, Rosenberg SA: Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J Exp Med 156:385–397, 1982.
Adler A, Stein JA, Kedar E, Naor D, Weiss DW: Intralesional injection of interleukin-2-expanded autologous lymphocytes in melanoma and breast cancer patients: A pilot study. J Biol Resp Modif 3:491–500, 1984.
Rosenberg SA: Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2. J Biol Resp Modif 3:501–511, 1984.
Mazumder A, Eberlein TJ, Grim EA, Wilsod D, Keenan AM, Aamodt R, Rosenberg SA: Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells. Cancer 53:896–905, 1984.
Slankard-Chahinian M, Holland JF, Gordon RE, Becker J, Ohnuma T. Adoptive autoimmunotherapy: Cytotoxic effect of an autologous long-term T cell line on malignant melanoma. Cancer 53:1066–1072, 1984.
Kohler PC, Hank JA, Exten R, Minkoff DZ, Wilson DG, Sondel PM: Clinical response of a patient with diffuse histiocytic lymphoma to adoptive chemoimmunotherapy using cyclophosphamide and alloactivated haploidentical lymphocytes: A case report and phase I trial. Cancer 55:552–560, 1985
Rosenberg SA, Lotze MT, Muul LM, Leitmann S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM: Observations on the systemic administration of autologous lymphokineactivated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485–1489, 1985.
Coakham HB, Lashmi MS: Tumor-associated surface antigen(s) in human astrocytomas. Oncology 31:233–243, 1975.
Wikstrand CJ, Mahaley MS, Bigner DD: Surface antigenic characteristics of human glial brain tumor. Cancer Rec 37:4267–4275, 1977.
Keheyov IR: Tumor-associated water soluble antigen(s) in human glioblastoma demonstrated by immunodiffusion and immunoelectrophoresis. Ann Immunol 127c:703–716, 1976.
Pfreundschuh M, Shiku H, Takahashi T: Serological analysis of cell surface antigens of malignant human brain tumors. Proc Natl Acad Sci USA 75:5122–5126, 1978.
Levy NL: Specificity of lymphocyte-mediated cytotoxicity in patients with primary intracranial tumors. J Immunol 121:903–915, 1978.
Rainbird S, Allwood G, Ridley A: Lymphocyte-mediated cytotoxicity against gliomas. Brain 104:451–464, 1981.
Young HF, Kaplan A: Immunotherapy of human gliomas. In: Waters H (ed) Immunotherapy. The handbook of cancer immunology. Garland STPM Press, New York, 1978, Vol 5, pp 375–382.
Young HF, Kaplan A, Regelson W: Immunotherapy with autologous white cell infusions (‘lymphocytes’) in the treatment of recurrent glioblastoma multiforme. A preliminary report. Cancer 40:1037–1044, 1977.
Scher I, Maje MG: Cellular identification and separation. In: Paul WE (ed) Fundamental immunology. Raven Press, New York, 1984, pp 767–780.
Hünig TR, Bevan MJ: Antigen recognition by cloned cytotoxic T lymphocytes followed rules predicted by the alteredself hypothesis. J Exp Med 155:111–117, 1982.
Karnofsky DA, Ableman WH, Craver LF, Burchenal JH: The use of the nitrogen mustards in the palliative treatment of carcinoma with particular reference to bronchogenic carcinoma. Cancer 1:634–656, 1948.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kitahara, T., Watanabe, O., Yamaura, A. et al. Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor. J Neuro-Oncol 4, 329–336 (1987). https://doi.org/10.1007/BF00195603
Issue Date:
DOI: https://doi.org/10.1007/BF00195603